tiprankstipranks
Advertisement
Advertisement
Compass Pathways sees cash runway into 2028
PremiumThe FlyCompass Pathways sees cash runway into 2028
3d ago
Neuronetics price target lowered to $3 from $7 at Canaccord
Premium
The Fly
Neuronetics price target lowered to $3 from $7 at Canaccord
8d ago
COMPASS Pathways: Durable Psychedelic Therapy Profile and Clear Path to 2027 Approval Support Buy Rating
Premium
Ratings
COMPASS Pathways: Durable Psychedelic Therapy Profile and Clear Path to 2027 Approval Support Buy Rating
12d ago
Compass Pathways 17.5M share Secondary priced at $8.00
PremiumThe FlyCompass Pathways 17.5M share Secondary priced at $8.00
1M ago
Compass Pathways price target raised to $22 from $21 at RBC Capital
Premium
The Fly
Compass Pathways price target raised to $22 from $21 at RBC Capital
1M ago
Compass Pathways price target raised to $18 from $11 at Morgan Stanley
Premium
The Fly
Compass Pathways price target raised to $18 from $11 at Morgan Stanley
1M ago
COMPASS Pathways Reports Positive Phase 3 Results in TRD
PremiumCompany AnnouncementsCOMPASS Pathways Reports Positive Phase 3 Results in TRD
1M ago
Compass Pathways achieves primary endpoint in Phase 3 COMP006 trial
Premium
The Fly
Compass Pathways achieves primary endpoint in Phase 3 COMP006 trial
1M ago
Psychedelic: Clearmind reports additional CMND-100 safety results
Premium
The Fly
Psychedelic: Clearmind reports additional CMND-100 safety results
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100